|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Ra Pharmaceuticals Inc (RARX)
WEIGHTED MOVING AVERAGE
Trading: SELL @ $46.9
Signal Strength: STRONG
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to highlight trends across numerous timeframes. This indicator has the ability to smooth historical results to illustrate trend initiation and status. Although this is a simple trend following indicator & can provide good results when coupled with the right indicator. Note, this indicator does not work well in ranging markets producing unwanted whipsaws and false signals.
Ra Pharmaceuticals Inc (NASDAQ:RARX) currently has a confirmed downtrend. Recent trading has caused the WMA 15 day average to move below the closing price confirming the short term trend following indicator. Currently, the return on WMA15 is 0.1%.
Weighted moving averages (WMA) are difficult to construct but more reliable than the simple moving averages. WMA permits an unequal weighting on prior time periods.
Calculation: Weighted Moving Average (WMA):
1) Ft= W1At-1 + WnAt-n
PROFILE: Ra Pharmaceuticals Inc (RARX)
Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
|SYRS Syros Pharmaceuticals||8.2||4.9||153,243||-0.5||BEARISH|
|BCOR Blucora Inc||23.41||3.2||401,986||-2.8||BEARISH|
|VSEC VSE Corporation||34.74||3||14,243||-2.1||BEARISH|
|VRAY Viewray Inc||3.06||3||3,697,594||-4.6||BEARISH|
|ALGN Align Technology||279.31||2.2||795,665||-1.5||BEARISH|
|NTLA Intellia Therapeutics||14.64||1.9||548,959||-0.3||BEARISH|
|PRTK Paratek Pharma||3.69||1.7||644,839||-3.6||BEARISH|
|PLSE Pulse Biosciences||14.24||1.7||41,876||-1.2||BEARISH|
|ATRS Antares Pharma||4.24||1.7||878,188||-2.4||BEARISH|